AnaptysBio will separate its business into two public companies in the second quarter of 2026, potentially as early as late April, carving out its R&D engine as First Tracks Biotherapeutics while the parent retains the AnaptysBio name to manage substantial royalty assets from Jemperli with GSK and imsidolimab with Vanda. A Form 10 has been filed for the spin, and First Tracks will launch with ANB033 (a CD122 antagonist) in Phase 1b for celiac disease and an initiated cohort in eosinophilic esophagitis, rosnilimab (a pathogenic T-cell depleter) post–Phase 2b in rheumatoid arthritis, and ANB101 (a BDCA2 modulator) in Phase 1a. The royalty company projects meaningful near- and midterm cash flows underpinned by Jemperli’s Q4 2025 sales of $343 million, implying a roughly $1.4 billion annualized run rate, and expects more than $390 million in annualized royalties at GSK’s peak sales guidance of more than $2.7 billion as early as 2029.
This is more than corporate housekeeping; it is a bid to solve the biotech valuation puzzle by disentangling cash-yielding royalty streams from inherently volatile clinical risk. In an environment where small- and mid-cap biotechs still face a high cost of capital, creating a royalty-centric entity with line-of-sight to accelerating immuno-oncology receipts could reduce the conglomerate discount, while giving First Tracks the strategic coherence to partner, sequence trials, and control spend without competing against a royalty cash waterfall for investor mindshare.
The timing matters for multiple stakeholders. For oncology prescribers and payers, GSK’s accelerated push into earlier-stage, biomarker-selected colorectal and head and neck settings with Jemperli, including a pivotal Phase 2 in untreated locally advanced dMMR/MSI-H rectal cancer and other perioperative programs, signals continued movement of PD-1 inhibitors up the treatment curve where duration and total addressable population can expand meaningfully. If label expansions arrive on expedited review pathways, payer scrutiny will shift to comparative value in adjuvant and organ-preserving strategies; Medical Affairs teams should prepare for pragmatic evidence generation and perioperative care pathway integration. On the dermatology front, FDA acceptance of the BLA for imsidolimab in generalized pustular psoriasis with a target action date of December 12, 2026, sets a clear inflection for the royalty company’s non-oncology diversification.
For immunology competitors, First Tracks’ bet on CD122 antagonism is notable. By targeting the IL-2/IL-15 receptor beta chain, ANB033 aligns squarely with celiac disease biology, where IL-15–driven epithelial stress fuels pathology. The Phase 1b design spanning gluten-challenge prevention and mucosal healing cohorts, with topline data expected in the fourth quarter of 2026, is structured to speak to both regulatory plausibility and real-world commercial relevance. In eosinophilic esophagitis, ANB033 enters a crowded but still-evolving space dominated by Th2-targeted biologics; differentiation on histologic and symptomatic endpoints, dosing convenience, and steroid-sparing impact will be decisive with payers and gastroenterologists. Meanwhile, rosnilimab’s future in rheumatoid arthritis appears contingent on external capital or partnerships—a pragmatic signal that First Tracks will selectively own versus out-license based on mechanism and competitive intensity. ANB101’s early profile, positioned against BDCA2 precedents, could benefit from clearer pharmacodynamic depth and durability if validated clinically, but investor memory of class volatility will demand robust, mechanism-linked biomarkers.
Anaptys ended 2025 with $311.6 million in cash and investments and has repurchased 11.2% of shares outstanding, while its $600 million non-recourse royalty monetization with Sagard is projected to be fully paid down by the end of Q2 2027, potentially freeing greater unencumbered cash flows thereafter. The strategic question now is whether public markets will reward a pure-play royalty vehicle with visible oncology momentum while granting First Tracks a cost of capital low enough to prosecute mid-stage immunology efficiently. Watch for spin completion timing, Jemperli readouts in 2026 that set the royalty glidepath, and ANB033’s late-2026 data to determine if this split creates two investable leaders—or merely two smaller targets in a still-consolidating biotech landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
